文献速递肿瘤 PET/CT甲状腺核医学

并非所有PSMA表达骨病灶都是前列腺癌:分期68Ga-PSMA-11 PET/CT偶然检出转移性分化型甲状腺癌

Not Every PSMA-Expressing Bone Lesion Is Prostate Cancer: Incidental Detection of Metastatic Differentiated Thyroid Carcinoma on Staging 68Ga-PSMA-11 PET/CT.
PubMed 文献 · Clin Nucl Med · 2026-10-20

本文报道一例新诊断高危前列腺腺癌患者行68Ga-PSMA-11 PET/CT分期,除原发前列腺病灶外,胸骨和右侧甲状腺叶可见PSMA表达病灶;骨骼受累最初被推测为前列腺癌转移,进一步评估证实为滤泡变异型乳头状甲状腺癌。该病例提示重要诊断陷阱,并展示PSMA-PET/CT发现临床隐匿同步恶性肿瘤的价值。

要点

  • 68Ga-PSMA-11 PET/CT可因肿瘤新生血管PSMA表达检出非前列腺恶性肿瘤。
  • 胸骨PSMA表达病灶并非一定是前列腺癌骨转移,需进一步评估。
  • 本例胸骨病灶最终证实为滤泡变异型乳头状甲状腺癌转移。

核心结论

  • 68Ga-PSMA-11 PET/CT分期中发现的PSMA表达骨病灶并非均为前列腺癌转移,应警惕同步其他恶性肿瘤。

研究设计与样本

  • 本文为病例报告,报告一例新诊断高危前列腺腺癌患者行68Ga-PSMA-11 PET/CT分期。

主要发现

  • 除原发前列腺病灶外,胸骨和右侧甲状腺叶可见PSMA表达病灶。
  • 骨骼受累最初被推测为前列腺癌转移,进一步评估证实为滤泡变异型乳头状甲状腺癌。

临床怎么用

  • 对68Ga-PSMA-11 PET/CT上PSMA表达的非前列腺典型部位病灶,应结合进一步评估排除同步恶性肿瘤。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

68Ga-PSMA-11-PET/CT is widely used for staging prostate cancer but may also detect nonprostatic malignancies owing to prostate-specific membrane antigen (PSMA) expression in tumor neovasculature. Here, we report a case of a newly diagnosed high-risk prostate adenocarcinoma that underwent staging 68Ga-PSMA-11-PET/CT. In addition to the primary prostatic lesion, PSMA-expressing lesions were identified in the sternum and right thyroid lobe. While skeletal involvement was initially presumed metastatic prostate cancer, further evaluation revealed follicular variant papillary thyroid carcinoma. This case highlights an important diagnostic pitfall and demonstrates the value of PSMA-PET/CT in uncovering clinically occult synchronous malignancies.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Wagle A, Satapathy S, Suresh A, et al. Not Every PSMA-Expressing Bone Lesion Is Prostate Cancer: Incidental Detection of Metastatic Differentiated Thyroid Carcinoma on Staging 68Ga-PSMA-11 PET/CT. Clin Nucl Med. 2026. PMID: 42912561. doi:10.1097/RLU.0000000000006719

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。